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Abstract  
A novel synthetic methodology for preparing amide conjugates of the DO3A-N-(-
amino)propionate chelator is described, using the synthesis of the DO3A-N-(-
benzoylamido)propionate chelator as an illustrative example.  The model Gd(DO3A-N-
(-benzoylamido)propionate) chelate displays accelerated water exchange, stability in a 
wide pH range and inertness towards transmetallation by Zn
2+
.  The Gd(DO3A-N-(-
benzoylamido)propionate) complex is mainly excreted via the kidneys, producing a 
significant increase of the kidney medulla/cortex enhancement ratio in MR images of 
Wistar rats, reflecting probably its increased hydrophobicity compared to Gd(DTPA). 
The results presented suggest that Gd(DO3A-N-(-amido)propionate) chelates can be 
valuable leads for preparing potentially safe high relaxivity MRI contrast agents. 
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Introduction 
Since its introduction around 30 years ago, MRI has evolved into the leading 
imaging modality both in the clinics and in biomedical sciences (1). Incremental 
developments in instrumentation, particularly the use of increasingly higher magnetic 
fields, and the use of contrast agents (CAs), have driven MRI to the forefront of medical 
imaging (2). Gd
3+
 chelates are the most useful CAs for MRI due to the high 
paramagnetism (7 unpaired electrons) and long electronic relaxation times of the Gd
3+
 
ion (3). To ensure safety, Gd
3+
 ions are used as complexes with poly(aminocarboxylate) 
ligands, which prevents the inherent toxicity of the free metal ion and modulates its 
unfavorable pharmacokinetic behaviour. The efficacy of a CA is measured by its 
relaxivity (r1, r2)- the enhancement of the relaxation rate of the water protons brought 
about by a 1 mM concentration of Gd
3+ 
(4,5). Increasing detection sensitivity, by 
maximizing relaxivity, has been the driving force in the development of new CAs (6). 
Nonetheless, the high relaxivities predicted theoretically haven’t yet been achieved in 
spite of the tremendous efforts and developments in the field (7). The main approaches 
to enhance detection sensitivity involve optimizing the relaxivity of individual chelates, 
clustering a high number of (high relaxivity) chelates into (bio)macromolecular carriers 
or self-assembly of monomeric chelates into supramolecular structures, and directing 
chelate constructs to the sites of interest by attaching targeting moieties recognized 
specifically by cellular receptors (6,8). All these approaches require chemical 
modification of the basic chelator structure in order to introduce “handles” for chemical 
functionalization.        
A few years ago, the discovery of severe toxicity associated with repeated CA 
MRI in individuals suffering from kidney function impairment cast doubt about the 
safety of MRI CAs (9,10). This condition, named Nefrogenic Systemic Fibrosis (NSF), 
owing to generalized formation of fibrotic (scarring) plates in the skin and internal 
organs, was correlated with the use of Gd
3+
 chelates of DTPA bis-amide chelators (11). 
Release of Gd
3+
 ions in vivo, owing to insufficient kinetic and thermodynamic stability 
of the Gd(DTPA-bis-amide) chelates, seems the most likely reason for CA toxicity 
(12,13). Importantly, only a few cases have been associated with macrocyclic CAs of 
the DOTA family, all in patients suffering from kidney disease (13-15). The much 
higher kinetic and thermodynamic stability of the macrocyclic DOTA-type CAs 
precludes release of Gd
3+
 ions in vivo. The adoption of stricter guidelines concerning the 
use of Gd
3+
-based CA has drastically reduced the number of NSF cases reported (16). 
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Nonetheless, safety, associated to chelate stability, rather than high relaxivity (high 
detection sensitivity), is becoming the new paradigm in CA MRI, which favours the use 
of macrocyclic, DOTA-type CAs. There are several CAs of this type approved for 
clinical use in Europe, most of which are extracellular CAs. Gd(HPDO3A) (Prohance
®
) 
has become one of the CAs of choice in the clinical setting (17). Improving the 
performance of DOTA-type CAs (targeting, multimerization, responsiveness, etc.) 
requires chemical elaboration of the basic DOTA scaffold to allow conjugation to 
(bio)molecules. Endowing DOTA chelators with conjugability without compromising 
stability is a core problem in CA research. In fact, the most convenient route for 
chemical functionalization of the DOTA skeleton, differentiating an acetate arm for 
amide coupling, reduces the thermodynamic and kinetic inertness of  Gd(DOTA-
monoamide)-type chelates (18). Furthermore, neutral Gd(DOTA-monoamide)-type 
chelates display much slower water exchange, limiting the relaxivities potentially 
achievable by chelates displaying optimized rotational correlation times (R). 
Introducing pendant functional groups on the ethylenediamine bridges on the DOTA 
skeleton is an effective, although costly solution (19). It is preferable from the synthetic 
point of view to elaborate the (pre-formed) available cyclen skeleton than starting 
chelator synthesis from scratch. We have recently reported the synthesis of a new 
chelator, DO3A-N-(-amino)propionate (L2, Scheme 1) and the relaxometric 
characterization of its Gd
3+
 complex. The -amino substituted propionate arm 
presumably imposes steric compression around the water binding site on the complex, 
resulting in an accelerated water exchange rate kex (20). In the same year, Botta and co-
workers reported a bifunctional chelator, DOTAMAP-En, and an amide conjugate, 
DOTAMAP-En-C18, bearing a propionamide arm. Even higher water exchange rates 
were demonstrated for the Gd(DOTAMAP-En) and for the Gd(DOTAMAP-En-C18) 
chelates, presumably also owing to steric compression (21). The kex value for the 
Gd(DO3A-N-(-amino)propionate) (GdL2) chelate is of the same order of magnitude as 
that reported for its (unsubstituted) propionate analogue Gd(DOTA-N-propionate)- in 
the range considered ideal for attaining high relativities at intermediate/high field 
(18,20,22). Moreover, the GdL2 complex is stable in the pH range 2-10 and inert 
towards transmetallation with Zn
2+
. The pendant available amine group is ideal for 
conjugation through a variety of ligation chemistries.  
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We have recently reported the preparation of a cysteinyl conjugate of the DO3A-
N-(-amino)propionate chelator using an advanced  protected intermediate on route to 
the DO3A-N-(-amino)propionate chelator, as originally proposed (23). However, an 
important issue remains to be addressed: what is the effect of amide conjugation on the 
stability and water exchange rate of Gd(DO3A-N-(-amido)propionate) chelates? In 
this manuscript we describe a novel expeditious methodology for the synthesis of amide 
conjugates of the DO3A-N-(-amino)propionate chelator. The relaxometric 
characterization and in vivo MRI evaluation of a model amide chelate, Gd(DO3A-N-(-
benzoylamido)propionate) (GdL1), is reported.   
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Results and Discussion 
Synthesis  
Allying stability to conjugability is an important requisite for developing metal 
chelates into imaging and/or therapeutic agents. We have proposed before that the 
pendant amine group on the -aminopropionate arm on the DO3A-N-(-
amino)propionate chelator is an ideal handle for conjugation to (bio)molecules (20).  
There are literature precedents for the direct conjugation of functionalised (pre-formed) 
chelates (24). However, solubility issues and difficult manipulations and purifications 
can be avoided, especially with radio-labelled metal chelates, by labelling fully 
deprotected conjugates. A cysteinyl conjugate of the DO3A-N-(-amino)propionate was 
recently described by us using the “conventional approach”: amide coupling of a S,N-
protected cysteinyl block to a protected advanced intermediate followed by deprotection 
(23).  In this work we disclose a new expeditious strategy for the synthesis of amide 
conjugates of the DO3A-N-(-amino)propionate scaffold (Scheme 1). 
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Scheme 1. Synthetic sequence for  the DO3A-N-(-benzoylamido)propionate ligand and its 
Gd
3+ 
chelate. a) K2CO3, MeCN; b) i. TFA/DCM, ii. K2CO3/ethyl bromoacetate, MeCN; c) i. 
Dowex 1X2100-OH- resin, ii. Elution with hydrochloric acid 0.1 M; d) GdCl3.xH2O.    
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Introducing a pre-formed Boc-dehydroamide (Ph, Boc)--AlaOMe 2 into the 
cyclen scaffold via Michael addition is the key step in this reaction sequence. Building 
up on our previous experience on the synthesis of bifunctional chelator L2 we envisaged 
that (Boc, amide)-dehydroalanines of type 2 could fulfil electronic and steric 
requirements to perform well as electrophiles in Michael addition to cyclen. (Boc, 
amide)-dehydroalanines of type 2 can be readily prepared in two steps from serine 
methyl ester hydrochloride 1 and stored at room temperature for extended periods (25). 
Michael addition of block (2) to cyclen 3 proceeded smoothly in acetonitrile, using 
K2CO3 as base, in 2-3 hours. An excess of cyclen, 1.5 eq., was used in order to bias the 
statistical mixture towards the monoalkylated product 4. Removing the Boc group at the 
monoalkylated intermediate 4 stage could avert retro-elimination during the next 
alkylation step. In fact, one pot treatment of 4 with TFA, followed by alkylation with 
ethyl bromoacetate in the presence of a large excess of K2CO3 produced the fully 
alkylated amide 5 in moderate yield without evidence of retro-elimination. One step 
deprotection of the fully alkylated pro-chelator 5 with ion-exchange resin Dowex 1X2 
OH
-
 followed by elution with hydrochloric acid yielded the fully deprotected DO3A-N-
(-benzoylamido)propionate chelator L1 in overall (non-optimised yield) of 16% over 3 
steps. Introducing the pre-formed amide onto the cyclen scaffold early on the synthesis 
is an unusual strategy. This conjugation strategy avoids orthogonal protection schemes 
and multistep deprotection for obtaining the final conjugates. Moreover, synthesising 
the amide separately and performing the “coupling” early on the synthesis avoids 
difficult purifications and reduces the risk of contamination of the final conjugates with  
bi-products of (carbodiimide-based) coupling reagents (23). This approach is general, 
applicable to Boc-dehydroamides of type 2 lacking acid sensitive moieties/protecting 
groups and basic sites susceptible to alkylation on the amide moiety.  
 
Solution NMR and relaxometric studies 
As discussed above, the aim of this work is to ascertain if Gd
3+
 chelates of amide 
conjugates of the DO3A-N-(-amino)propionate metal chelator retain the high stability, 
inertness and fast water exchange of its parent GdL2 complex. The soluble, low 
molecular weight GdL1 complex (Scheme 1) was selected as a model system in order to 
avoid solubility and self-assembly complicating issues.     
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1
H NMR spectra at 600 MHz of L1 complexes (Ln
3+
= La, Sm
 
and Eu) at 298 K 
and neutral pH were found to contain very broad resonances for the macrocyclic and 
pendant arm methylene protons, indicating the presence of an internal isomerisation 
process at intermediate exchange on the NMR time scale (26). The temperature 
dependence of the 
1
H spectrum of the EuL1 complex studied at lower frequency (300 
MHz) provides direct proof of this process. In fact, the spectrum at 280 K contains more 
than fifty sharp resonances, corresponding to slow exchange between two isomers of C1 
symmetry, which are broadened at higher temperature (Figure 1SI: Supporting 
Information). The large positive shifts of the two sets of four resonances observed in the 
low temperature spectrum result from the four axial protons of the Eu
3+
 complex in the 
square antiprismatic (SA) and  twisted square antiprismatic (TSA) conformations with a 
60:40 population ratio, while the parent EuL2 complex in the same conditions indicates 
a 98% predominance of the SA conformation (20). Thus, the derivatization of the amine 
function of L2 favours the TSA form. 
The water exchange rate, kex
298
, for the GdL1 complex was determined from 
variable-temperature 
17
O NMR studies (Figure 1 a and b). Additionally, the magnetic 
field dependence of the longitudinal water proton relaxivities (r1) was measured by 
1
H 
nuclear magnetic relaxation dispersion (NMRD) at 298 and 310 K (Figure 1c) with the 
objective of determining the parameters that describe water exchange and rotational 
dynamics for the GdL1 complex. 
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Figure 1. Temperature dependence of the (a) reduced transverse and longitudinal 
17
O 
relaxation rates 1/T2r and 1/T1r, and (b) chemical shifts r; B = 9.4 T (ln(1/T1r), (■), 
(ln(1/T2r), ()), and (c) NMRD profiles (298 K () and 310 K (■) for the Gd(DO3A-
N-(-benzoylamido)propionate) complex.   
 
The Solomon-Blombergen-Morgan theory was used for analyzing simultaneously the 
experimental 
1
H NMRD data, as well as the 
17
O NMR reduced longitudinal (1/T1r) and 
transverse (1/T2r) relaxation rates and chemical shifts (r) (5). In the analysis, the 
following parameters have been fitted: rate (kex
298
), activation enthalpy (ΔH‡) and 
activation entropy (ΔS‡) of the water exchange, the rotational correlation time (τRH
298
) 
and its activation energy (ER), the electron spin relaxation parameters (τV
298
, Δ2 and EV) 
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and the scalar coupling constant (A/ħ). The diffusion constant and its activation energy 
have been fixed to DGdH
298
 = 26 x 10
-10
 m
2
s
-1 
and EDGdH
298
 = 22 kJ/mol, respectively. 
The Gd-water proton distance was fixed to rGdH = 3.1Å, and the distance of closest 
approach between the Gd
3+
 ion and the outer sphere protons to GdH = 3.6 Å (22,27).  
The parameters obtained from the simultaneous fitting of the data are shown on Table 1, 
and the corresponding fitted curves are shown in Figure 1. 
 
Table 1. Best fit parameters obtained for the Gd(DO3A-N-(-
benzoylamido)propionate) chelate  from the simultaneous fitting of 
the NMRD data, 
17
O NMR longitudinal (1/T1r) and transverse 
(1/T2r) relaxation rates and chemical shifts (r).
 
 
 
 
 
 
 
 
 
 
 
 
  
           
In the fitting, one inner sphere water molecule was assumed in analogy with the 
parent GdL2 complex (20). This assumption was confirmed by the value obtained for 
the parameter A/ħ, characteristic of q = 1 complexes of the DOTA family. The rate 
constant for water exchange for the GdL1 complex (kex
298
 = (5.14 ±0.4) x 10
7
 s
-1
) is of 
the same order of magnitude as that reported for its parent GdL2 complex (kex
298
 = 
(4±0.4) x 10
7
 s
-1
) (20) and for the unsubstituted Gd(DOTA-N-propionate) complex 
(kex
298
 = 6.1 x 10
7
 s
-1
) (18). Moreover, kex is around one order of magnitude higher than 
that reported for Gd(DOTA)(27). This result confirms our working hypothesis, that 
Gd
3+ 
chelates of amide conjugates of the DO3A-N-(-amino)propionate chelator retain 
the fast water exchange displayed by its parent GdL2 complex. This is an important 
result, suggesting that amide conjugates displaying an optimized rotational correlation 
time, R, could attain high relaxivities at intermediate fields.  
Parameters GdL1
a GdL2
b 
Gd(DOTA)
c 
q(H2O)  1 1 1 
ΔH‡[J/K/mol] 17±1.1 19.1 54.5 
ΔS‡[kJ/mol] -40±6 -35 +65 
kex
298
 [10
7
 s
-1
] 5.14 ± 0.4 4 0.46 
ER [kJ/mol] 26.2±1.1 17 20 
τRH
298
[ps] 182±10 71 100 
EV [kJ/mol]  4.8±0.5 1 8.6 
τV
298
 [ps] 7.2±1.5 11 0.65 
Δ2 [1020 s-2] 0.5±0.06 0.25 0.12d 
A/ħ [106 rad/s] -3.13±0.4 -3.6 -4.0 
  a
Parameters underlined have been fixed. 
b
 From ref.(20). 
c
 From ref. 
(27). 
d
 From ref. (28) 
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The value for the rotational correlation time obtained from the 
1
H longitudinal 
relaxation rates (τRH
298
 = 182 ps) is characteristic of low molecular weight chelates, 
indicating that the complex does not self-assemble in the concentration range studied. 
At high magnetic fields, the relaxivity is dominated by fast rotation in solution, as 
demonstrated by its temperature dependence (Figure 2SI).  
Besides thermodynamic stability, the kinetic stability of the Gd
3+
 complexes is 
of paramount importance for meaningful biological applications. The in vivo 
dissociation of a GdL complex depends on the exchange reactions taking place in the 
blood plasma, such as with the most abundant bidentate anions like carbonate (~26 
mM), L-lactate (~2.3 mM), or phosphate (~1.1 mM) (29, 30). The time dependence of 
the relative water proton paramagnetic relaxation rate R1p(t)/R1p(0) for the GdL1 
complex in 10 mM phosphate buffer is shown in Figure 2. Addition of 6.7 equiv. of 
phosphate to a 1.5 mM solution of the complex causes a fast decrease in R1p of 10%, 
indicating a weak interaction of the complex with phosphate, possibly replacing the 
inner-sphere water molecule by adduct formation in a monodentate binding mode (31). 
Larger (~25% decreasing) effects of phosphate on the relaxivity of Gd
3+
 complexes with 
two inner-sphere water molecules have been observed (32).  
Metal exchange reactions with endogenous metal ions, the most abundant of 
which in blood plasma (besides Ca
2+
 and Mg
2+
) is Zn
2+ 
(29, 30), have been proposed to 
be the most likely mechanisms for Gd
3+
 leakage (33, 34). This can occur via the direct 
attack of the endogenous metal on GdL, or via proton-assisted dissociation of GdL, 
followed by recombination of the ligand with the attacking metal ion (35-37). Kinetic 
studies carried out close to physiological pH using much higher cationic concentrations 
than the free concentrations expected in plasma, led to the general conclusion that the 
dissociation of DTPA-like linear complexes occurs mainly via direct transmetallation, 
while the much slower dissociation of DOTA-like macrocyclic chelates uses mainly 
proton-assisted pathways (35-37).   
The kinetic inertness of the GdL1 complex was evaluated using the simple 
transmetallation assay developed by Muller and co-workers (38). Complex 
transmetallation by Zn
2+ 
was studied in phosphate-buffer (10 mM, pH 7.1) (Figure 2). 
Replacement of Gd
3+
 by Zn
2+
 in the initial complex generates a time-dependent 
decrease of the paramagnetic contribution to the water proton spin-lattice relaxation rate 
(R1p) due to precipitation of GdPO4.  
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The time evolution of the relative water proton paramagnetic relaxation rate 
R1p(t)/R1p(0) for the GdL1 complex in phosphate buffer, in the absence and in the 
presence of Zn
2+
 (Figure 2) fulfils the accepted empirical criteria for kinetic and 
thermodynamic stability (38). Although the Zn
2+
 concentrations used in this empirical 
assay are several orders of magnitude higher than its free or exchangeable 
concentrations in plasma (30), the results provide a fast initial screening between inert 
and labile Gd
3+
 complexes. Furthermore, the independence of the paramagnetic 
relaxation rates for the GdL1 complex from the solution pH (Figure 3SI) confirms that 
the complex is stable in the pH range 2-11. 
 
 
 
Figure 2. Evolution of the relative water proton paramagnetic relaxation rate R1p(t)/R1p(0) (20 
MHz, pH 7.1, 298 K) versus time for a 1.5 mM solution of Gd(DO3A-N-(-
benzoylamido)propionate complex in phosphate buffer (10 mM, pH 7.1) (○) and in phosphate 
buffer containing an equimolar amount of Zn
2+
 ions (●).  
 
The interaction of the GdL1 complex with human serum albumin (HSA) was 
studied by relaxometric titration (Figure 4SI). A very weak binding was detected, which 
is not likely to affect the pharmacokinetic behaviour of the complex in vivo.   
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MRI Studies  
Comparative MRI studies have been performed at 7.0 Tesla in male Wistar rats 
with GdL1 and Gd(DTPA). The GdL1 contrast agent was well tolerated by the animals 
at the dose used. No gross side effects were observed during the injection, immediately 
or several days after the experiment. During experiments, rats body temperature 
remained stable and no alteration on the body functions was observed. Overall, GdL1 
seemed to be harmless to the animals. Nevertheless, a more detailed study would be 
required to further assess its toxicology.  
Figure 3 shows a representative series of T1-weighted spin-echo axial images of 
the Dynamic Contrast Enhanced (DCE) experiments obtained before and after injection 
of the GdL1 complex (dose 0.1 mmol Gd/kg body weight) and, for comparison 
purposes, Gd(DTPA) at the same dose. In the pre-injection image, kidney structures 
(cortex, inner and outer medulla) and adjacent tissues were dark due to the particular 
inversion delay chosen. After bolus injection in the vascular system, a strong signal 
enhancement was observed in the kidneys for the two CAs, as a result of the T1 
shortening. A slighter signal enhancement was observed in liver and muscle for both 
CAs. As can be seen, both complexes follow mainly renal elimination by glomerular 
filtration with a very small hepatobiliary contribution to excretion.  
 
 
Figure 3. Representative coronal T1-weighted spin echo MR images of a Wistar rat before and 
after injection of the contrast agents (A) GdL1 (dose 0.1 mmol kg
-1
 BW), (B) Gd(DTPA) (dose 
0.1 mmol kg
-1
 BW). 
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The features of the data in Figure 3 are better understood as illustrated in Figure 
4, which shows their quantitative analysis. Each time point corresponds to the average 
intensity within ROIs placed on the different organs. In order to compare the results for 
all the animals under study (n = 4), the data were normalized by calculating the mean 
relative enhancement of each ROI. The scattering in the time course curves of the 
average relative enhancement of the ROIs was caused by animal respiratory motion. 
Muscle and liver enhancement is comparably low with both complexes. The relative 
enhancement obtained with Gd(DTPA) increased almost immediately after intravenous 
injection from 0 up to about 250% in the kidney medulla and 200% in the kidney 
cortex, followed by a steady decrease to values around 120% and 80%, respectively, 
after 50 minutes. The time course of the average relative enhancement after injection of 
Gd(DTPA) (Figure 4A) is in good agreement with the literature for Gd(DTPA) (39,40) 
or other low molecular weight Gd-based contrast agents (41-45). 
The renal pharmacokinetic behavior of GdL1 is significantly different from that 
observed for Gd(DTPA). Kidney cortex enhancement build-up is slower than for 
Gd(DTPA), reaching a maximum of about 100% after 10 minutes post injection, 
followed by a steady decrease to a value (~80%) comparable to that reached by 
Gd(DTPA) after 50 minutes.  
 
Figure 4. Time course of signal intensity, relative to the initial value (up to 50 min post-
injection) of several regions of interest during dynamic contrast enhancement MRI experiments 
in rats with (A) Gd(DTPA) (0.1 mmol kg
-1
 BW) and (B) GdL1 (0.1 mmol kg
-1
 BW). The time 
courses are data for mean values of four animals and the corresponding standard error. 
 
However, the main difference between GdL1 and Gd(DTPA) regards kidney 
medulla enhancement. While for Gd(DTPA) there is a sharp increase just after injection, 
followed by a steady decrease, for the GdL1 complex a saturation-like kinetic behaviour 
is observable.  
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After 50 minutes, a significantly higher enhancement of the kidney medulla is 
attained with the GdL1 complex comparing to Gd(DTPA) (200% vs 120%). At the same 
dose, the GdL1 complex resulted in a considerably lower initial signal enhancement 
than Gd(DTPA) at both the cortex and medulla, which is not in agreement with their in 
vitro relaxivities, which are comparable.  As a consequence of the disparate 
pharmacokinetics, the ratio of medulla/cortex enhancement increases significantly for 
the GdL1 complex over the duration of the experiment, while it is approximately 
constant for the Gd(DTPA) complex.  
The pharmacokinetic behaviour in rats of the Gd(DOTA) complex regarding 
kidney excretion is similar to that displayed by the Gd(DTPA) complex (41): a sharp 
enhancement of kidney medulla and cortex after injection followed by a steady decrease 
with the enhancement ratio medulla/cortex approximately constant over the experiment 
duration. This suggests that, although charge effects (-2 for the Gd(DTPA) complex and 
-1 for the GdL1 complex) cannot be ruled out, the observed difference of 
pharmacokinetic behaviour is likely due to the higher hydrophobicity of the GdL1 
complex comparing to the Gd(DTPA) complex.  
It has been shown previously that the in vitro and in vivo relaxivities of Gd-
based CAs can be significantly different, as the latter are affected by tissue structure and 
physiology (39,46). Gd(DTPA) was found to display relaxivities considerably lower in 
rat kidney cortex or medulla comparing to the values measured in saline solution or in 
other tissues. This effect is related to CA compartmentalization in the kidney (47,48). 
The quantitative determination of the in vivo relaxivity of a CA requires knowledge of 
its local concentration. In some cases, CA concentration has been obtained from 
independent measurements. These studies, however, are not without difficulties, since 
they often induce significant perturbations to the tissues, by studying intact excised 
tissues (49), making measurements post-mortem (47), or ensuring a constant infusion of 
the CA in order to establish a steady state concentration (48).  
Lacking such experiments, estimation of the relative in vivo relaxivities would 
require to measure the effective T1 values on different ROIs,  to assume a linear 
dependence of signal enhancement with the local CA concentration, and the 
unacceptable assumption of similar pharmacokinetics for Gd(DTPA) and GdL1 (43). 
Therefore, this quantitative pharmacokinetic study, which is beyond the scope of the 
present work, is not feasible in the present case.  
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One can safely conclude from the present study that the pharmacokinetic 
behaviour of both CAs is different, especially in the kidney medulla at later stages of 
excretion.  
 .    
Conclusions  
 In this manuscript we describe the synthesis of the benzoylamide conjugate of 
the DO3A-N-(-amino)propionate chelator as an illustrative example of a new, general 
methodology for the expeditious preparation of amide conjugates. The Gd(DO3A-N-(-
benzoylamido)propionate) chelate retains the fast water exchange and stability of its 
parent Gd(DO3A-N-(-amino)propionate) complex. 
  DCE-MRI studies in rats revealed that the Gd(DO3A-N-(-
benzoylamido)propionate) chelate is mainly excreted via the kidneys. A significant 
increase of the kidney medulla/kidney cortex enhancement ratio is produced by the 
contrast agent after 50 minutes, reflecting probably its increased hydrophobicity 
compared to Gd(DTPA). 
 The results presented here suggest that Gd(DO3A-N-(-amido)propionate) 
chelates are valuable leads for preparing potentially safe high relaxivity MRI CAs. In 
fact, Gd(DO3A-N-(-amido)propionate) chelates with optimized water exchange 
features, when bound to suitable carriers, are likely to originate high relaxivities at 
intermediate fields by virtue of the simultaneous optimisation of kex and R (23). The 
high relaxivities of such imaging platforms allied to chelate stability and safety could 
find many uses in biomedical and pre-clinical diagnostic MRI applications.  
 
Experimental 
Materials and Methods 
Chemicals were purchased from Sigma-Aldrich and used without further 
purification. Solvents used were of reagent grade and purified by usual methods. Cyclen 
was purchase from CheMatech. Reactions were monitored by TLC on Kieselgel 60 
F254 (Merck) on aluminium support. Detection was by examination under UV light 
(254 nm) and by adsorption of iodine vapour. Flash chromatography was performed on 
Kieselgel 60 (Merck, mesh 230–400). The relevant fractions from flash chromatography 
were pooled and concentrated under reduced pressure, T < 313 K. Ion exchange 
chromatography was performed on Dowex1X2100-OH
-
 resin (Sigma Aldrich).  
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The resin was purchase as the Cl
-
 form and converted to the OH
-
 form by the standard 
procedure. 
1
H and 
13
C NMR spectra (assigned by 2D DQF-COSY and HMQC 
techniques) were run on a Varian Unity Plus 300 NMR spectrometer, operating at 
299.938 MHz and 75.428 MHz, for 
1
H and 
13
C, respectively. Chemical shifts () are 
given in ppm relative to the CDCl3 solvent (
1
H,  7.27; 13C,  77.36) as internal 
standard. For 
1
H and 
13
C spectra recorded in D2O, chemical shifts () are given in ppm 
relative to TSP as internal reference (1H,   0.0) and tert-butanol as external reference 
(
13
C, CH3   30.29). The Gd
3+
 concentration of the complex preparation used for in vivo 
MRI was determined by inductively coupled plasma optical emission spectrometry 
(ICP-OES). 
   
(2-(N-t-butoxycarbonyl)benzamido)-methoxycarbonylethyl-1,4,7,10-
tetrazacyclododecane - monoalkylated cyclen (4): K2CO3 (4.07 g, 29.5 mmol) was 
added to a solution of cyclen (1.27 g, 7.37 mmol) in MeCN (50 ml). To this solution 
was added (Ph, Boc)--AlaOMe 2 (1.5 g, 4.91 mmol). The suspension was stirred 
vigorously at room temperature for 3 hrs. The suspension was filtered and the filtrate 
was evaporated under reduced pressure. The residue was purified by flash 
chromatography (100% CH2Cl2  CH2Cl2/EtOH/NH3/H2O (70:30:5:5)) to afford 
compound 4 as a viscous light yellow oil (1.34 g, 59.1%). 
1
H NMR (300 MHz, CDCl3): 
δ = 1.47 (s, 9H, Boc), 2.50-2.90 (m, 16H, N(CH2)2N), 3.01 (dd, J= 14.1 and 6 Hz, 1 H, 
NCHaHbCH), 3.49 (dd, J= 14.4 and 5.1 Hz, 1 H, NCHaHbCH), 3.76 (s, 3H, OMe), 5.25 
(t, J= 6 and 5.1 Hz, 1H, NCHaHbCH), 7.30-7.70 (5H, m, Ar). 
13
C NMR (75.4 MHz, 
CDCl3): δ= 27.27 (C(CH3)3), 44.77 (CH2), 45.83 (CH2), 46.70 (CH2), 51.27 (CH2), 
52.51 (OCH3), 55.61 (NCH2CH), 56.08 (CH), 83.88 (C(CH3)3), 127.87 (Ar), 127.96 
(Ar), 131.27 (Ar), 137.02 (Ar), 152.72 (NC(O)O), 170.57 (C(O)Ar), 172.62 
(C(O)OCH3). HRMS (ESI): m/z: cacd for C24H39N5O5: 478.3029, found: 478.3024. 
 
2-benzamido-methoxycarbonylethyl-4,7,10-tris-(ethoxycarbonylmethyl)-1,4,7,10-
tetrazacyclododecane- tetraalkylated cyclen (5)- :A solution of monoalkylated cyclen 
4 (1.30 g, 2.72 mmol) in a solution of trifluoroacetic acid in dichlorometane (60%, 25 
ml) was stirred overnight at room temperature. The solvent was evaporated at reduced 
pressure and the residue was redissolved in dichloromethane. This procedure was 
repeated several times to give a light yellow thick oil. 
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1
H NMR spectroscopy (CDCl3) revealed the disappearance of the signals assigned to 
the Boc groups in the precursor compound 4. Quantitative deprotection was assumed. 
To a solution of Boc-deprotected compound 4 (2.72 mmol, assuming quantitative 
deprotection) in MeCN (40 ml) was added K2CO3 (4.51 g, 32.6 mmol). The suspension 
was vigorously stirred for 30 minutes at room temperature before adding ethyl 
bromoacetate (1.06 ml, 9.52 mmol). The suspension was further stirred at room 
temperature for 2.5 hrs. The suspended solid was removed by filtration, the filtrate was 
evaporated under reduce pressure and the residue was purified by flash chromatography 
(100% CH2Cl2  CH2Cl2/EtOH (1:1)) to afford compound 5 (0.632 g, 37%) as a white 
foam. 
1
H NMR (300 MHz, CDCl3): δ= 1.22 (m, 9 H, CH2CH3),  2.2-3.60 (broad, 
overlapped signals with a integration corresponding to, 24 H, NCH2 and NCHaHbCH), 
3.71 (s, 3H, C(O)OCH3), 5.14 (m (br), 1H, NCHaHbCH), 7.44-8.03 (5H, m, Ar). 
13
C 
NMR (75.4 MHz, CDCl3): selected signals: 13.95 (CH2CH3), 48.74 (CH),  49.04 (CH2), 
50.38 (CH2), 51.48 (CH2),  52.59 (CH2), 52.95 (OCH3), 53.62 (CH2CH), 53.62 (CH2), 
54.86 (CH2), 54.96 (CH2), 55.19 (CH2), 55.37 (CH2), 55.75 (CH2), 56.18 (CH2),  60.62 
(CH2), 60.94, 61.13, 61.21 (OCH2), 127,83 (Ar), 128,12 (Ar), 128,41 (Ar), 131,53 (Ar),  
131,84 (Ar), 132.62 (Ar), 167.79 (C(O)Ar), 170.29 (2X C(O)OCH2), 170.52 
(C(O)OCH3), 170.91 (C(O)OCH2). HRMS (ESI): m/z: cacd for C31H49N5O9: 636.3609, 
found: 636.3590. 
 
2-benzamido-carboxyethyl-4,7,10-tris-(carboxymethyl)-1,4,7,10-
tetrazacyclododecane - DO3A-N-(-benzoylamido)propionate metal chelator (L1): 
Compound 5 (0.566 g, 0.89 mmol) was dissolved in a mixture made up of 20 ml of 
water and 20 ml of ethanol. The solution was adjusted to pH ~ 10-11 by adding small 
portions of Dowex 1X2-100-OH
- 
resin. The suspension was kept under stirring at room 
temperature for 2 hours. The wet resin was transferred into a chromatography column, 
washed with water (~50 ml) and eluted with 0.1 M hydrochloric acid. The relevant 
fractions, identified by TLC (ethanol water 1/1, revelation with iodine vapor) were 
pooled, concentrated at room temperature and further dried under vacuum to afford the 
final deprotected compound, in the hydrochloride form,  as a light yellow solid (6) 
(0.276 g, 71.2%). 
1
H  NMR (300 MHz, CDCl3): δ= 2.9-3.6 (broad, overlapped signals 
with a integration corresponding to, 18 H, N(CH2)2N and NCHaHbCH), 3.81 (broad, 
overlapped signals with a integration corresponding to, 6 H, NCH2), 4.80 (m (br), 
1
H, 
CH), 7.53-7.88 (5H, m, Ar). 
13
C NMR (75.4 MHz, CDCl3): selected signals: 43.02 
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(CH2), 48.11 (CH2), 48.93 (CH2), 49.03 (CH2), 49.78 (CH2), 51.39 (CH2),  51.71 (CH), 
51.91 (CH2), 54.53 (CH2), 56.08 (CH2), 56.77 (2x CH2), 127,46 (2x Ar), 129,04 (2x 
Ar), 132,60 (Ar), 133.32 (Ar), 170.20 (C(O)), 177.17 (C(O)Ar). HRMS (ESI): m/z: 
cacd for C24H36N5O9: 538.2513, found: 538.2508. 
 
1
H and 
17
O NMR and 
1
H NMRD experiments  
Sample preparation 
To an aqueous solution of the ligand (pH = 5.0) was added drop-wise an aqueous 
solution of the corresponding LnCl3.xH2O lanthanide in a 1:1 mole ratio. The solution 
was stirred at room temperature over 1 hour while keeping its pH at around 5.7 by 
adding aqueous KOH. The solution was keft stirring at room temperature overnight.  
The solution was concentrated under reduced pressure to afford off white solids. The 
solutions for NMR measurements were obtained by dissolution of the appropriate 
amounts of solid complexes in D2O (V = 1 ml) to obtain 20 mM concentrations. Proton 
1D spectra of the solutions of the paramagnetic (Sm
3+
 and Eu
3+
) and diamagnetic (La
3+
)
 
complexes were obtained at 298 K on a Varian VNMRS 600 (14.09 T, 600.14 MHz) 
NMR spectrometer and the temperature dependence of the 
1
H NMR spectra of the Eu
3+
 
complex on a Varian Unity Plus 300 NMR spectrometer. 
The solutions of the GdL1 complex for 
17
O NMR and 
1
H NMRD experiments 
were prepared by mixing equimolar amounts of GdCl3 and ligand. A slight excess (5%) 
of ligand was used. The solution was adjusted to pH ~5.8 with aqueous NaOH and was 
allowed to react for 24 hours at room temperature. The absence of free metal was 
checked in each sample by testing with xylenol orange (50,51). HPLC analysis (RP C18 
silica, isocratic elution with acetonitrile/water (70:30), detection at = 265 nm) of an 
aqueous solutiom of the Gd(DO3A-N-(-benzoylamido)propionate) complex (8 mM, 
pH 7.0) indicates that the complex is > 95 pure (Figure 5SI). The pH of the stock 
solution was adjusted by adding aqueous NaOH (0.1 mM). 
17
O-enriched water (
17
O: 
11.4%) was added to the solutions for 
17
O measurements to improve sensitivity. The 
final concentration of the complex solution was 17.56 mmol kg
-1
 at pH = 6.90. For the 
NMRD experiments a 5.00 mM solution of complex at pH 6.98 was used. 
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17
O NMR experiments 
Variable-temperature 
17
O NMR measurements were performed on a Bruker 
Avance-500 (11.7 T) spectrometer. A BVT-3000 temperature control unit was used to 
stabilize the temperature, measured by a substitution technique. The samples were 
sealed in glass spheres that fitted into 10 mm o.d. NMR tubes, to eliminate 
susceptibility corrections to the chemical shifts (41). Longitudinal relaxation rates (1/T1) 
were obtained by the inversion recovery method, and transverse relaxation rates (1/T2) 
by the Carr-Purcell-Meiboom-Gill spin-echo technique. As an external reference, 
acidified water of pH 3.4 was used.  
 
NMRD measurements 
The measurements were performed by using a Stelar Spinmaster FFC NMR 
relaxometer (0.01–20 MHz) equipped with a VTC90 temperature control unit. At higher 
fields, the 
1
H relaxivity measurements were performed on a Bruker Electromagnet at the 
frequencies of 30 MHz, 40 MHz, 60 MHz and 80 MHz. In each case, the temperature 
was measured by a substitution technique. Variable temperature measurements were 
performed at 25 and 37
◦
C. 
 
Relaxivity studies of pH dependence and Zn
2+ 
transmetallation  
The transmetallation reaction of GdL1 with Zn
2+
 was studied by following the 
time dependent decrease of the water proton longitudinal relaxation rate, R1, of a 
phosphate-buffered saline solution (PBS, pH 7.1, 10 mM) containing 1.5 mM of GdL1 
after adding an equimolar amount of ZnCl2 while the sample was vigorously stirred 
(53).  The water longitudinal relaxation rate was also measured as a function of time on 
the PBS buffered solution (pH 7.1, 10 mM) containing 2.5 mM GdL1 (54). The pH 
dependence of the relaxivity of the GdL1 solution was also measured. A Bruker 
Minispec mq20 (20 MHz, 298 K) relaxometer was used for all measurements. 
 
MRI experiments 
In vivo MRI studies. The experimental protocols performed were approved by the 
appropriate institutional review committees and meet the guidelines of their responsible 
governmental agency.  
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The Magnetic Resonance Imaging (MRI) experiments were all performed on a Bruker 
Pharmascan platform (Bruker Medical Gmbh, Ettlingen, Germany) using a 7.0 T 
horizontal-bore superconducting magnet, equipped with a 
1
H selective 60 mm birdcage 
resonator and a Bruker gradient insert with 90 mm diameter (maximum intensity 360 
mT/m). Data were acquired using a Hewlett-Packard console running Paravision 
software (Bruker Medical Gmbh, Ettlingen, Germany) under a LINUX environment.  
All MRI examinations were carried out on male Wistar rats (n = 4, 250-260 g body 
weight) anaesthetized initially by inhalation in an induction box with O2 (1 l/min) 
containing 3 % isoflurane, and maintained during the experiment using a face mask 
allowing free breathing and 1-2 % isoflurane on O2. Animals were taped down into a 
holder, to minimize breathing-related motion, and were then placed in a heated probe, 
which maintained the core body temperature at 37 ± 0.5 °C, monitored by a rectal probe. 
The physiological state of the animal was monitored throughout the entire experiment 
by a Biotrig physiological monitor (Bruker Medical Gmbh, Ettlingen, Germany), using 
the respiratory rate and body temperature. 100 mM solutions of Gd(DO3A-N-(-
benzoylamido)propionate (GdL1) and  Gd(DTPA) (Magnevist

, Schering, Berlin, 
Germany) were prepared in distilled water and the pH was adjusted to 7.2. The 
solutions were injected into the catheterized tail vein as a bolus in 20 s (0.1 mmol 
Gd.kg
-1
 body weight) using an infusion pump (Panlab, Barcelona, Spain). Regional 
contrast agent uptake was assessed using Dynamic Contrast Enhanced (DCE) MRI.  
DCE MRI experiments were performed with series of T1-weighted spin echo images 
sequentially acquired over 1 h, before and following the injection of the contrast agent 
10 min after the beginning of the study. The acquisition parameters were: TR = 310 ms, 
TE = 10.58 ms, number of averages = 2, ten coronal slices, slice thickness = 2 mm, 
FOV = 5.0 x 5.0 cm, matrix = 256 x 256, 30 repetitions with a total acquision time of 
119 s.  
MRI data analysis. Data were analyzed with the public domain software Image J 
(http://rsbweb.nih.gov/ij/). With the aim of comparing the pharmacokinetics obtained 
from different animals, the data were normalized by calculating the percentage of 
relative, rather than absolute, enhancement: 
   100
)(
0
0 


I
II
RE  
where I is the signal intensity at any given time after CA injection and I0 is the intensity 
before injection.  
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The pharmacokinetic behaviour was analyzed by calculating the average enhancements 
within the different regions of interest (ROIs) placed on each one of the following 
regions: liver, kidney medulla, kidney cortex and muscle.  
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Supplementary Information. Figure 1SI: 1H NMR spectra (300 MHz) for the EuL1 
complex at different temperatures (280 K (7 ºC), 298 K (25 ºC), 313 K (40ºC) and 333 
K (60 ºC) and neutral pH.  
Figure 2SI: Temperature dependency of the water proton longitudinal paramagnetic  
relaxation rate R1p (20 MHz, 25 ºC) for a GdL1 solution (1.5 mM, pH 7.0).  
Figure 3SI: pH dependency of the water proton longitudinal paramagnetic relaxation 
rate R1p (20 MHz, 25 ºC) for a 1.5 mM solutiom of GdL1. 
Figure 4SI: Concentration dependency of the water proton longitudinal paramagnetic 
relaxation rate R1p (20 MHz, 25 ºC, pH = 7.1) for GdL1 solutions in water (triangles) 
and in the presence of 4% (0.6 mM) HSA in water (circles) and in a phosphate buffer 
(PBS, 5 mM) (diamonds).  
Figure 5SI: HPLC chromatogram (RP C18 silica, isocratic elution with 
acetonitrile/water (70:30), detection at 265 nm) for a GdL1 aqueous solution (8 mM, 
pH 7.0). 
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Supporting Information 
 
 
Figure 1SI. 
1
H NMR spectra (300 MHz, D2O) for the Eu(DO3A-N-(-
benzoylamido)propionate) complex at different temperatures. 
 
Figure 2SI. Temperature dependency of the water proton longitudinal paramagnetic 
relaxation rates R1p (20 MHz, 25 ºC) for a 1.5 mM solution of Gd(DO3A-N-(-
benzoylamido)propionate. 
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Figure 3SI. pH dependency of the water proton longitudinal paramagnetic relaxation 
rates R1p (20 MHz, 25 ºC) for a 1.5 mM solution of Gd(DO3A-N-(-
benzoylamido)propionate. 
 
 
 
 
Figure 4SI. Dependency of  the water proton longitudinal paramagnetic relaxation rates 
on the concentration of the GdL1 complex in water (triangles), and  in the presence of  
4% (0.6 mM) HSA (circles) in water and in a phosphate buffer (PBS, 5 mM, pH = 7.1) 
(diamonds) (20 MHz, 298 K). 
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Figure 5SI: HPLC chromatogram (RP C18 silica, isocratic elution with 
acetonitrile/water (70:30), detection at 265 nm) for a GdL1 aqueous solution (8 mM, 
pH 7.0).  
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Equations used for the analysis of NMRD and 
17
O NMR data 
 
NMRD and 
17
O NMR data have been analysed within the framework of the Solomon-
Bloembergen-Morgan theory.  
 
 
17
O NMR spectroscopy 
 
From the measured 
17
O NMR relaxation rates and angular frequencies of the 
paramagnetic solutions, 1/T2 and , and of the acidified water reference, 1/T2A and , 
one can calculate the reduced relaxation rates and chemical shifts, 1/T2r and r, which 
may be written as in Equations (A1)-(A2), where, 1/T2m is the relaxation rate of the 
bound water and m is the chemical shift difference between bound and bulk water, m 
is the mean residence time or the inverse of the water exchange rate kex and Pm is the 
mole fraction of the bound water. 
[1, 2] 
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Previous studies have shown that outer sphere contributions to the 
17
O relaxation rates 
are negligible. 
[3] 
 
In equation (A2) the chemical shift of the bound water molecule, m, depends on the 
hyperfine interaction between the Gd
III
 electron spin and the 
17
O nucleus and is directly 
proportional to the scalar coupling constant, 

A
, as expressed in Equation (A3). 
[4] 
 

A
T
)B+S(Sμg
=Δω
B
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m
3k
1
 (A3) 
 
The isotopic Landé g factor is equal to 2.0 for the Gd
III
, B represents the magnetic field, 
and kB is the Boltzmann constant. 
 
The outer-sphere contribution to the chemical shift is assumed to be linearly related to 
Δωm  by a constant Cos [Equation (A4)]. 
[5] 
 
 
Δωos= C osΔωm  (A4) 
 
In the transverse relaxation, the scalar contribution, 1/T2sc, is the most important 
[Equation (A9)]. 1/s1 is the sum of the exchange rate constant and the electron spin 
relaxation rate.  
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The exchange rate is supposed to obey the Eyring equation. In equation (A7) S‡ and 
H‡ are the entropy and enthalpy of activation for the water exchange process, and 
kex
298
 
 
is the exchange rate at 298.15 K. 
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NMRD 
The measured longitudinal proton relaxation rate, R1
obs
= 1/T1
obs
, is the sum of a 
paramagnetic and a diamagnetic contribution as expressed in Equation (A12), where r1 
is the proton relaxivity: 
 
][+R=R+R=R +dpdobs 311111 Gdr  (A8) 
 
The relaxivity can be divided into an inner and an outer sphere term as follows: 
 
1os1is1 r+r=r  (A9) 
 
The inner sphere term is given in Equation (A14), where q is the number of inner sphere 
water molecules. 
[6] 
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The longitudinal relaxation rate of inner sphere protons, 1/T1m
H
 is expressed by 
Equation (A11), where rGdH is the effective distance between the electron charge and the 
1
H nucleus, I is the proton resonance frequency andS is the Larmor frequency of the 
Gd
III
 electron spin. 
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where RH is the rotational correlation time of the Gd-Hwater vector. 
 
 
The rotational correlation time, RH is assumed to have simple exponential temperature 
dependence with an ER activation energy as given in equation (A13). 
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The outer-sphere contribution can be described by Equation (A14) where NA is the 
Avogadro constant, and Jos is its associated spectral density function as given by 
Equation (A15). 
[8, 9] 
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The longitudinal and transverse electronic relaxation rates, 1/T1e and 1/T2e are expressed 
by Equation (A16)-(A17), where v is the electronic correlation time for the modulation 
of the zero-field-splitting interaction, Ev the corresponding activation energy and 
2
 is 
the mean square zero-field-splitting energy. We assumed a simple exponential 
dependence of v versus 1/T as written in Equation (A18). 
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The diffusion coefficient for the diffusion of a water proton away from a Gd
III
 complex, 
 33 
DGdH, is assumed to obey an exponential law versus the inverse of the temperature, with 
an activation energy EDGdH, as given in Equation (A19). DGdH
298
 is the diffusion 
coefficient at 298.15K. 
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